Kura Oncology’s FIT-001 Phase I dose-escalation trial of KO-2806, a farnesyl transferase inhibitor (FTI) for the treatment of advanced solid tumours, has commenced with the dosing of the first patient. FIT-001 is a first-in-human, multicentre, open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary… Read More
Listen to this article on the DDW Podcast: Diana Spencer catches up with Lorna Ewart, PhD, Chief Scientific Officer of Emulate, about the rise of organ-on-a-chip technology. Organ-chips combine cell culture with microfluidics to emulate the biological forces of different organ tissues and/or disease states, allowing pharmaceutical researchers to determine a… Read More
Register for the DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, to hear insight and expertise from leading figures. It will be hosted by DDW and sponsored by Taconic Biosciences. The event will take place online on 16 November at 7AM PST /… Read More
Iksuda Therapeutics has dosed the first patient in a Phase I trial of antibody drug conjugate (ADC) IKS014 in patients with advanced solid tumours that express HER2. This follows positive data from Phase I clinical trials through Fosun Pharma, which is now progressing FS-1502 (IKS014) through… Read More
iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumour survival pathways, has published new research data in the peer-reviewed journal Cancer Research, that supports a strategy of combining autotaxin inhibitor IOA-289 with TGF-β pathway inhibitor IOA-359. Resistance to TGF‐β… Read More
Gamida Cell has revealed early data in 10 patients with CD20 positive non-Hodgkin lymphoma as part of an ongoing study of natural killer (NK) cell therapy candidate GDA-201. The multicentre Phase I study is designed to evaluate safety and determine the maximum tolerated dose. Read More
The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’ will take place online on 16 November at 7AM PST / 10AM EST / 3PM GMT / 4PM CET. This free summit, sponsored by Taconic Biosciences, will offer expert thought leadership… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. To celebrate DDW’s first Turning Science into Business Summit on ‘Cancer research… Read More
News round-up for 16-20 October by DDW Digital Content Editor Diana Spencer. To celebrate DDW’s first Turning Science into Business Summit on ‘Cancer research opportunities and advances’, the news round-up this week highlights the latest developments in oncology drug discovery. The top stories:… Read More
CARsgen has published evidence of over seven years of disease-free survival in advanced hepatocellular carcinoma (HCC) following treatment with its CAR-GPC3 T cell therapy. Hepatocellular carcinoma is one of the most common malignant tumours, with approximately 780,000 annual incidence cases globally. Recurrence and metastasis are common. Read More
The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’ will feature experts and thought leaders in cancer research, precision medicine and immunotherapy. Andreas Dreps DDW is delighted to confirm that ICON’s SrVP and Global Head of Science Andreas Dreps and… Read More
The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’ will feature an expert panel discussion on new drug discovery and development concepts and tools in cancer research. The free two-hour Summit, hosted by DDW, will take place online on 16… Read More
Join DDW’s Megan Thomas and Reece Armstrong with sponsor Taconic Biosciences for the first DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, on 16 November at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. This free 2-hour… Read More
Join DDW for its Turning Science into Business Summit: Cancer research opportunities and advances. This free online event will be hosted by DDW and is sponsored by Taconic Biosciences. The 2-hour Summit will outline areas of advancement and opportunity in the cancer research market and will consist of presentations from… Read More
Merck and The Institute of Cancer Research (ICR), London, UK, have renewed their strategic alliance in the discovery and development of new cancer drugs. Scientists in the Centre for Cancer Drug Discovery at the ICR will work with researchers at Merck to discover and develop new… Read More
University of Queensland (UQ) researchers have identified a novel drug target with the potential to overcome drug resistance and prevent tumour regrowth in cancer patients. The newly identified molecule is not currently a target for treatment, opening the potential for drug development. “Drug resistance… Read More
